Heart attack

Ethris and Heqet Therapeutics have revealed plans to collaborate on RNA-based therapeutics for heart attack and heart failure, using non coding RNAs (ncRNAs) in regenerating heart tissue. Under the terms of the agreement, Heqet Therapeutics will lead the development of the programme, while Ethris will provide its proprietary Stabilized NanoParticle (SNaP) LNP platform to deliver […]

DDW’s Reece Armstrong speaks to Hendrik Streefkerk, Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases.   Based in France, CellProthera is a small, regenerative cell therapy developer that specialises in cardiovascular diseases. The […]

Serca Pharmaceuticals, a cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, has presented data on a novel approach to modulate the beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility.  The study aimed […]

A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK under a new agreement.  The Phase IIb LIBERATE study will test the tolerance and the efficacy of glenzocimab 1000mg to reduce heart damage following a myocardial infarction (MI). According to the partnership between the University of […]

A drug candidate for heart attacks which contains venom from a deadly spider has moved closer to clinical trials due to investment of $23 million.  A research team at the University of Queensland have developed a potential therapy for heart attacks and stroke which uses a molecule found in the venom of the K’gari (Fraser […]